PEAK6 Group’s Niagen Bioscience NAGE Stock Holding History

PEAK6 Group’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-13,874	Closed	-$53K	–	5134
2017 Q2	$53K	Buy	+13,874	New	+$43.9K	﹤0.01%	4102

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

NSIM

North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

PEAK6 Group's NAGE Position: Q3 2017 in Review

PEAK6 Group sold out of Niagen Bioscience (NAGE) in Q3 2017, closing a stake of 13,874 shares — an estimated $53K sold.

PEAK6 Group first reported a position in NAGE in Q2 2017 and held it in 1 quarter. The position peaked at $53K in Q2 2017. 42 funds tracked by Wall St. Rank hold NAGE as of Q3 2017.

PEAK6 Group reported no remaining Niagen Bioscience position as of Q3 2017 after selling out during the quarter.
PEAK6 Group sold 13,874 Niagen Bioscience shares in Q3 2017, an estimated $53K.
PEAK6 Group first reported a position in Niagen Bioscience in Q2 2017 and held it in 1 quarter.
PEAK6 Group's Niagen Bioscience position peaked at $53K in Q2 2017.
42 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2017.

Based on PEAK6 Group's 13F filing for Q3 2017, filed 14 Nov 2017.